Table 1.
Patient, tumor, and treatment characteristics for the study population (n = 100)
| Parameter | Result |
|---|---|
| Median age at surgery, yr (IQR) | 71 (64–75) |
| Sex (n) | |
| Female | 34 |
| Male | 66 |
| ASA score (n) | |
| 1 | 14 |
| 2 | 52 |
| 3 | 33 |
| 4 | 1 |
| Bladder cancer (n) | |
| Previous | 9 |
| Synchronous | 7 |
| Tumor location (n) | |
| Renal pelvis | 78 |
| Proximal ureter | 7 |
| Both locations | 15 |
| Tumor side (n) | |
| Right side | 38 |
| Left side | 62 |
| Preoperative FDG PET/CT (n) | 53 |
| Median TDmax, cm (IQR) | 4 (3–5) a |
| Clinical tumor stage (n) | |
| cT1 (N+) | 2 |
| cT2 | 28 |
| cT3 | 67 |
| cT4 | 3 |
| Clinical nodal stage (n) | |
| cN0 | 71 |
| cN1 | 8 |
| cN2 | 21 |
| Preoperative chemotherapy (n) | |
| Neoadjuvant | |
| MVAC | 9 |
| Induction | |
| MVAC | 10 |
| GCa | 5 |
| Adjuvant systemic therapy (n) | |
| MVAC | 3 |
| GC | 1 |
| GCa | 8 |
| Nivolumab | 2 |
ASA = American Society of Anesthesiologists; IQR = interquartile range; FDG = fluorodeoxyglucose; PET/CT = positron emission tomography/computed tomography; TDmax = maximum tumor diameter; MVAC = methotrexate, vinblastine, adriamycin, and cisplatin; GC = gemcitabine and cisplatin; GCa = gemcitabine and carboplatin.
a
Data from radiology and/or pathology report; values missing for 16 patients.